Dual-point Competition Association Assay: a Fast and High-throughput Kinetic Screening Method for Assessing Ligand-receptor Binding Kinetics
Overview
Authors
Affiliations
The concept of ligand-receptor binding kinetics is emerging as an important parameter in the early phase of drug discovery. Since the currently used kinetic assays are laborious and low throughput, we developed a method that enables fast and large format screening. It is a so-called dual-point competition association assay, which measures radioligand binding at two different time points in the absence or presence of unlabeled competitors. Specifically, this assay yields the kinetic rate index (KRI), which is a measure for the binding kinetics of the unlabeled ligands screened. As a prototypical drug target, the adenosine A(1) receptor (A(1)R) was chosen for assay validation and optimization. A screen with 35 high-affinity A(1)R antagonists yielded seven compounds with a KRI value above 1.0, which indicated a relatively slow dissociation from the target. All other compounds had a KRI value below or equal to 1.0, predicting a relatively fast dissociation rate. Several compounds were selected for follow-up kinetic quantifications in classical kinetic assays and were shown to have kinetic rates that corresponded to their KRI values. The dual-point assay and KRI value may have general applicability at other G-protein-coupled receptors, as well as at drug targets from other protein families.
Structure-affinity and structure-residence time relationships of macrocyclic Gα protein inhibitors.
Voss J, Crusemann M, Bartling C, Kehraus S, Inoue A, Konig G iScience. 2023; 26(4):106492.
PMID: 37091255 PMC: 10119753. DOI: 10.1016/j.isci.2023.106492.
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.
IJzerman A, Jacobson K, Muller C, Cronstein B, Cunha R Pharmacol Rev. 2022; 74(2):340-372.
PMID: 35302044 PMC: 8973513. DOI: 10.1124/pharmrev.121.000445.
Hit-to-lead and lead optimization binding free energy calculations for G protein-coupled receptors.
Wan S, Potterton A, Husseini F, Wright D, Heifetz A, Malawski M Interface Focus. 2020; 10(6):20190128.
PMID: 33178414 PMC: 7653344. DOI: 10.1098/rsfs.2019.0128.
van der Velden W, Heitman L, Rosenkilde M ACS Pharmacol Transl Sci. 2020; 3(2):179-189.
PMID: 32296761 PMC: 7155193. DOI: 10.1021/acsptsci.0c00012.
Huang S, Chen L, Mei H, Zhang D, Shi T, Kuang Z Int J Mol Sci. 2020; 21(7).
PMID: 32252223 PMC: 7177943. DOI: 10.3390/ijms21072456.